MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $30.829M Est

Benzinga Newsdesk www.benzinga.com Negative 66.5%

Neg 66.5% Neu 0% Pos 0%

MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 million-$32.000 million vs $30.829 million estimate.